Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSXenin-25 is an endogenous peptide and a neurotensin (NTS) receptor ligand.1 It binds to NTS receptors in HEK293 cell membranes expressing the mouse receptor. It is expressed in K cells in the small intestine and co-secreted with glucose-dependent insulinotropic polypeptide (GIP).2 Xenin-25 (1 µM) stimulates the release of insulin in BRIN-BD11 rat pancreatic β-cells in the presence of glucose and increases the insulinotropic response of glucagon-like peptide 1 (GLP-1), GIP, and neurotensin in the same cells.2 It prevents increases in plasma glucose levels in mice when administered 30 minutes before a subcutaneous injection of glucose. Xenin-25 inhibits gastric acid release stimulated by pentagastrin (Item No. 28546), increases pancreatic protein secretion, and stimulates contraction of the jejunum in anesthetized dogs.3
WARNING This product is not for human or veterinary use.
1. Stable expression of the mouse levocabastine-
2. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. J. Endocrinol. 207(1), 87-93 (2010).
3. Gastroenteropancreatic effects of xenin in the dog. J. Pept. Res. 49(4), 324-330 (1997).